New IMI Project to revolutionise Clinical Trials for Alzhemer's drugs

11.12.2013

IMI

Published 11 December 2013

- €53 million project will test new approach to clinical trials for drugs designed to prevent Alzheimer’s disease

  • - New approach will allow evaluation of several drugs at once
  • - Unique project will see several biotechnology and pharmaceutical companies work together with universities, small and medium-sized enterprises, patient groups and regulators
  • BRUSSELS, 11 December 2013 – The Innovative Medicines Initiative (IMI) is launching a major new project that will pioneer a novel, more flexible approach to clinical trials of drugs designed to prevent Alzheimer’s disease. The €53 million project, which will see several biotechnology and pharmaceutical companies working closely together, will aim to speed up drug development and patient access to the latest treatments. The announcement comes as the UK hosts a G8 summit dedicated to dementia in London on 11 December.

    There is an urgent need for new treatments for Alzheimer’s disease. The number of people affected worldwide is expected to reach 100 million by 2050, yet despite intensive efforts over many years, there is still no cure for Alzheimer’s and little in the way of treatments.

    The new project will focus its efforts on improving the system of ‘proof of concept’ studies, early stage clinical trials in which researchers seek to determine if a candidate drug is safe and has an impact on the disease in humans. Currently, companies carry out these trials individually. Each trial costs a lot of money, lasts several years, and may require thousands of patients, half of whom are treated with a placebo.

    The full Press Release is available here.